Key result
Emerging treatment options for pulmonary arterial hypertension utilizing novel mechanisms beyond the traditional nitric oxide, prostacyclin, and endothelin pathways are reviewed.
Why the study?
Current PAH therapies targeting three traditional pathways have extended lifespan, but significant morbidity and mortality remain, prompting a review of emerging treatments with novel mechanisms.
This review highlights emerging therapies for pulmonary arterial hypertension that target novel pathways beyond the traditional nitric oxide, prostacyclin, and endothelin pathways.
Emerging PAH therapies beyond the classic pathways may expand options; leaves open their impact on outcomes in rigorous trials.
Pulmonary arterial hypertension (PAH) is a devastating disease mediated by vasoconstriction and vascular remodeling of the pulmonary vasculature. Current therapies target the imbalance of vasoconstrictors and vasorelaxants in 3 pathways: nitric oxide, prostacyclin, and endothelin. While these have extended lifespans for PAH patients, significant morbidity and mortality remains. Notably, the progress in PAH therapy for over a decade has utilized these same 3 pathways. Fortunately, several new treatment options utilizing different mechanisms are emerging and will be reviewed here.
No takes yet. Share an insight, caveat, or question.
Keen et al. (2023) conducted a review in Pulmonary arterial hypertension (PAH). Emerging PAH therapies was evaluated. Emerging treatment options for pulmonary arterial hypertension utilizing novel mechanisms beyond the traditional nitric oxide, prostacyclin, and endothelin pathways are reviewed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: